Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilitie...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ning, Yan, Limei, Shan, Fengping, Wang, Xiaonai, Qu, Na, Handley, Mike K, Ma, Mingxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859308/
https://www.ncbi.nlm.nih.gov/pubmed/33540155
http://dx.doi.org/10.1016/j.tranon.2021.101028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859308/
https://www.ncbi.nlm.nih.gov/pubmed/33540155
http://dx.doi.org/10.1016/j.tranon.2021.101028

Ejemplares similares